{"analyses":[{"ciLowerLimit":"0.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.43","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2451","paramType":"Hazard Ratio (HR)","paramValue":"0.60","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.684","upperLimit":"40.674","value":"10.908"},{"groupId":"OG001","lowerLimit":"3.975","upperLimit":"19.647","value":"10.645"},{"groupId":"OG002","lowerLimit":"9.692","upperLimit":"46.752","value":"25.758"},{"groupId":"OG003","lowerLimit":"8.641","upperLimit":"20.041","value":"13.437"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"61"}],"units":"Participants"}],"description":"DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\\> background; 2=UT≤mediastinum;3=UT\\>mediastinum but ≤liver;4=UT moderately\\>liver;5=UT\\>than liver \\&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \\& residual mass of any size at interim for LN \\& ELS;residual UT\\>UT in normal bone marrow but\\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \\& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Arm C (Phase II Randomization): Pola+BR in DLBCL"},{"description":"Participants with DLBCL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG001","title":"Arm D (Phase II Randomization): BR in DLBCL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG002","title":"Arm F (Phase II Expansion): Pola+BG in DLBCL"},{"description":"Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG003","title":"Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)","title":"DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC","type":"SECONDARY","unitOfMeasure":"months"}